LB Pharma (LBRX): Price to Sales

Brandmark of LB Pharma (LBRX)

LB Pharmaceuticals Inc (LBRX) faces intense pressure from industry behemoths and high risks in developing schizophrenia treatments. To optimize formula discovery, the company is implementing bioinformatics software to automate routine analysis. Research is conducted in in-house laboratories, while the production of trial batches is delegated to contractors. Assessing the company's P/S monitoring on GURU.Markets, we find that determines this parameter level.

lbpharma.us - LBRX P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for LB Pharma (LBRX)

- share price and consensus valuation forecast:
Price Performance Chart lbpharma.us|LBRX - Price Target Chart
- stock exchange capitalization data:
Market Value LB Pharma|LBRX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share LB Pharmaceuticals|LBRX - Book Capitalization|Market Value to Book Value Ratio lbpharma.us|LBRX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio LB Pharmaceuticals Inc|LBRX - Long-Term Debt to Equity|Current Liabilities to Equity LB Corp|LBRX - Company Aggregate Debts|Debt to Net Assets Ratio LB Pharma|LBRX - Company Long-Term Debts|Company Short-Term Debts LB Pharmaceuticals|Intermediate Coverage Ratio lbpharma.us
- financial results and valuation multiples details:
LBRX - Company Net Income|Future Profit LB Pharmaceuticals Inc|LBRX - P/E Multiple|Forward P/E Multiple LB Pharmaceuticals, Inc.|LBRX - PEG Multiple|Enterprise Value to EBITDA Ratio LB Pharma|LBRX - Operating profit EBITDA|Net earnings per one share for the last twelve months LB Pharmaceuticals|LBRX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth lbpharma.us|LBRX - Net earnings per share growth this year|Projected earnings per share increase next year LB Pharmaceuticals Inc
- issuer revenue and sales details:
LBRX - Revenue and Sales Volume|Company Future Sales lbpharma.us|LBRX - P/S Multiple|Forward Price-to-Revenue Multiple LB Pharma
General company analysis:lbpharma.us, LBRX
Finished products of LB Pharmaceuticals, Inc.

Investors utilize multiples to verify an asset's market value relative to its operational success. By analyzing the current P/S ratio of LB Pharmaceuticals Inc (LBRX), you are assessing the ratio of market capitalization to annual sales volume, which is critical for LB Pharmaceuticals Inc (LBRX) as regulatory risks and the anticipation of late-stage clinical trials for its schizophrenia drug are already priced into this market valuation.

Competing companies

ALKS (alkermes.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Avadel Pharmaceuticals plc AVDL|atai Life Sciences NV (ATAI) - Price to Sales|GHRS - Price-to-Revenue Ratio|MNMD: Price-to-Revenue Ratio|CMPS: P/S Multiple|DRUG (brightmindsbio.com) - Price-to-Revenue Ratio|Market Cap to Revenue VNDA|CYBN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alto Neuro (ANRO)|NRXP: Price-to-Sales Ratio|P/S Multiple CING (Cingulate)|Market Capitalization-to-Revenue Ratio SILO|China Pharma - P/S Multiple|CMND - P/S Multiple|Psyence Biomedical Limited (PBM) - Price-to-Revenue Ratio|SciSparc Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Seelos Therapeutics|Market Cap to Revenue Virpax (VRPX)|P/S Multiple KRTX